Invivyd to Participate in Upcoming Investor Events
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) will join several June 2026 investor events, including the Jefferies Global Healthcare Conference in New York, the H.C. Wainwright “HCW @ Home” Series, and BTIG Infectious Disease Day 2026.
Fireside chats will be webcast and archived on Invivyd’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – IVVD
In the May 27 session, IVVD gained 2.73%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.2% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:
2026 Jefferies Global Healthcare Conference in New York
Fireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ET
Location: New York, NY
Webcast Link
H.C. Wainwright “HCW @ Home” Series
Fireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ET
Location: Virtual
Webcast Link
BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
1x1 Meetings
Location: Virtual
Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived following each event.
The management team will host investor meetings at the Jeffries Conference, following the H.C. Wainwright Virtual Fireside Chat, and as part of the BTIG Infectious Disease Day 2026. Investors participating in these events who are interested in meeting with Invivyd management should contact their Jeffries, H.C. Wainwright, or BTIG representatives.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com